MTA2 Antibody (F-9): sc-55566

MTA2 Antibody (F-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects MTA2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). MTA2 (F-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. MTA2, also known as Metastasis Associated 1 Family Member 2, plays a crucial role in gene expression regulation and is a key component of the nucleosome remodeling and histone deacetylation (NURD) complex. This complex is essential for ATP-dependent chromatin remodeling and transcriptional repression, as MTA2 facilitates repressor protein recruitment to chromatin, thereby influencing cellular processes such as differentiation and proliferation. MTA2 shares significant homology with MTA1, possessing similar functional domains that contribute to cancer progression. MTA2 expression levels can serve as a biomarker for assessing malignancy in cancers such as breast and colorectal carcinoma. MTA2′s ability to modulate chromatin structure and gene expression underscores MTA2′s importance in both normal cellular function and disease states, making anti-MTA2 antibody (F-9) a valuable tool for researchers studying cancer biology and epigenetic regulation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MTA2 Antibody (F-9) References:

1. Role of MTA2 in human cancer.  |  Covington, KR. and Fuqua, SA. 2014. Cancer Metastasis Rev. 33: 921-8. PMID: 25394532
2. MTA2 triggered R-loop trans-regulates BDH1-mediated β-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells.  |  Zhang, H., et al. 2021. Signal Transduct Target Ther. 6: 135. PMID: 33795651
3. Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma.  |  Huang, X., et al. 2023. Biomolecules. 13: PMID: 37371463
4. Loss of MTA2-mediated downregulation of PTK7 inhibits hepatocellular carcinoma metastasis progression by modulating the FAK-MMP7 axis.  |  Hu, HM., et al. 2024. Environ Toxicol. 39: 1897-1908. PMID: 38050825
5. A MTA2-SATB2 chromatin complex restrains colonic plasticity toward small intestine by retaining HNF4A at colonic chromatin.  |  Gu, W., et al. 2024. Nat Commun. 15: 3595. PMID: 38678016
6. Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines.  |  Toh, Y., et al. 1995. Gene. 159: 97-104. PMID: 7607577
7. A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses.  |  Toh, Y., et al. 1994. J Biol Chem. 269: 22958-63. PMID: 8083195
8. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression.  |  Heinzel, T., et al. 1997. Nature. 387: 43-8. PMID: 9139820
9. Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis.  |  Toh, Y., et al. 1997. Int J Cancer. 74: 459-63. PMID: 9291440
10. cDNA cloning of a novel, developmentally regulated immediate early gene activated by fibroblast growth factor and encoding a nuclear protein.  |  Paterno, GD., et al. 1997. J Biol Chem. 272: 25591-5. PMID: 9325278
11. NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities.  |  Xue, Y., et al. 1998. Mol Cell. 2: 851-61. PMID: 9885572
12. Molecular cloning, mapping, and characterization of a novel human gene, MTA1-L1, showing homology to a metastasis-associated gene, MTA1.  |  Futamura, M., et al. 1999. J Hum Genet. 44: 52-6. PMID: 9929979

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-MTA2 Antibody (F-9) has 19 citations in a variety of scientific publications.

Primary antibodies like Anti-MTA2 Antibody (F-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

MTA2 Antibody (F-9) Specifications

Alternate Product Name: PID

Product Clone Name: F-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 499-668

Epitope Target: MTA2

Epitope Species: human

Product Reactivity/Detection: MTA2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 19 citations in various scientific publications

Available Conjugates/Forms for MTA2 Antibody (F-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin